BioLife Gives Another Opportunity To Investors

  • The shares of BioLife have sold off last month, and those of competitor CryoPort much more, closing what we thought was an irrational valuation gap.
  • Critics argue that this is a commodity business but we see little or no signs of that.
  • The big money is in their clients reaching commercial production after FDA approval, CryoPort simply got more lucky here compared to BioLife, but it will happen there as well.
  • The near certainty of increasing commercial scale customers is also why these companies deserve high valuation multiples.

Source: BioLife Gives Another Opportunity To Investors – BioLife Solutions, Inc. (NASDAQ:BLFS) | Seeking Alpha